Published in J Biol Chem on April 03, 2003
Transcription factor Nrf1 mediates the proteasome recovery pathway after proteasome inhibition in mammalian cells. Mol Cell (2010) 2.24
Antioxidants enhance mammalian proteasome expression through the Keap1-Nrf2 signaling pathway. Mol Cell Biol (2003) 2.19
Proteasome-mediated processing of Nrf1 is essential for coordinate induction of all proteasome subunits and p97. Curr Biol (2014) 2.01
A proteasome for all occasions. FEBS Lett (2007) 1.84
Cellular stress response pathways and ageing: intricate molecular relationships. EMBO J (2011) 1.66
Role of proteasomes in disease. BMC Biochem (2007) 1.65
Regulation of proteasome activity in health and disease. Biochim Biophys Acta (2013) 1.52
The ubiquitin-proteasome system in cardiac proteinopathy: a quality control perspective. Cardiovasc Res (2009) 1.36
Proteotoxic crisis, the ubiquitin-proteasome system, and cancer therapy. BMC Biol (2014) 1.29
Progressively impaired proteasomal capacity during terminal plasma cell differentiation. EMBO J (2006) 1.27
Dynamics of the degradation of ubiquitinated proteins by proteasomes and autophagy: association with sequestosome 1/p62. J Biol Chem (2011) 1.24
Protein quality control and degradation in cardiomyocytes. J Mol Cell Cardiol (2008) 1.22
Loss of nuclear factor E2-related factor 1 in the brain leads to dysregulation of proteasome gene expression and neurodegeneration. Proc Natl Acad Sci U S A (2011) 1.20
Identification and characterization of a Drosophila proteasome regulatory network. Mol Cell Biol (2005) 1.18
Proteasome functional insufficiency in cardiac pathogenesis. Am J Physiol Heart Circ Physiol (2011) 1.11
Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo. Cancer Res (2010) 1.10
Validation of the proteasome as a therapeutic target in Plasmodium using an epoxyketone inhibitor with parasite-specific toxicity. Chem Biol (2012) 1.09
Use of RNA interference and complementation to study the function of the Drosophila and human 26S proteasome subunit S13. Mol Cell Biol (2003) 1.08
Thioredoxin Txnl1/TRP32 is a redox-active cofactor of the 26 S proteasome. J Biol Chem (2009) 1.08
The RPN5 subunit of the 26s proteasome is essential for gametogenesis, sporophyte development, and complex assembly in Arabidopsis. Plant Cell (2009) 1.05
Ubiquitin receptors and protein quality control. J Mol Cell Cardiol (2012) 1.04
Genomic analysis of Drosophila neuronal remodeling: a role for the RNA-binding protein Boule as a negative regulator of axon pruning. J Neurosci (2008) 1.03
Immunoproteasome subunit LMP2 expression is deregulated in Sjogren's syndrome but not in other autoimmune disorders. Ann Rheum Dis (2006) 1.02
The Arabidopsis proteasome RPT5 subunits are essential for gametophyte development and show accession-dependent redundancy. Plant Cell (2009) 1.01
Basic leucine zipper protein Cnc-C is a substrate and transcriptional regulator of the Drosophila 26S proteasome. Mol Cell Biol (2010) 0.99
Protection of peroxiredoxin II on oxidative stress-induced cardiomyocyte death and apoptosis. Basic Res Cardiol (2008) 0.98
Tripeptidyl peptidase II. An oligomeric protease complex from Arabidopsis. Plant Physiol (2005) 0.98
Aging and dietary restriction alter proteasome biogenesis and composition in the brain and liver. Mech Ageing Dev (2009) 0.96
Nrf2, a regulator of the proteasome, controls self-renewal and pluripotency in human embryonic stem cells. Stem Cells (2014) 0.96
Genome-wide analysis identifies MYND-domain protein Mub1 as an essential factor for Rpn4 ubiquitylation. Mol Cell Biol (2007) 0.95
Proteasomal degradation of Rpn4 in Saccharomyces cerevisiae is critical for cell viability under stressed conditions. Genetics (2009) 0.94
A proteasome inhibitor-stimulated Nrf1 protein-dependent compensatory increase in proteasome subunit gene expression reduces polycomb group protein level. J Biol Chem (2012) 0.94
Disruption of Rpn4-induced proteasome expression in Saccharomyces cerevisiae reduces cell viability under stressed conditions. Genetics (2008) 0.92
From the gastrointestinal tract (GIT) to the kidneys: live bacterial cultures (probiotics) mediating reductions of uremic toxin levels via free radical signaling. Toxins (Basel) (2013) 0.91
Molecular basis of differential sensitivity of myeloma cells to clinically relevant bolus treatment with bortezomib. PLoS One (2013) 0.91
Assessing subunit dependency of the Plasmodium proteasome using small molecule inhibitors and active site probes. ACS Chem Biol (2014) 0.90
The ubiquitin proteasome system and myocardial ischemia. Am J Physiol Heart Circ Physiol (2012) 0.90
Proteasome dysfunction triggers activation of SKN-1A/Nrf1 by the aspartic protease DDI-1. Elife (2016) 0.89
Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am J Pathol (2006) 0.88
Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies. Antioxid Redox Signal (2014) 0.85
Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells. Mol Vis (2007) 0.85
Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats. PLoS One (2013) 0.85
The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma. J Biol Chem (2015) 0.85
Proteome complexity and the forces that drive proteome imbalance. Nature (2016) 0.84
Inhibition of proteasomal degradation of rpn4 impairs nonhomologous end-joining repair of DNA double-strand breaks. PLoS One (2010) 0.83
A bright approach to the immunoproteasome: development of LMP2/β1i-specific imaging probes. Bioorg Med Chem (2011) 0.83
Immediate early gene-X1 interferes with 26 S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2. Biochem J (2007) 0.83
Sequence-specific alterations of epitope production by HIV protease inhibitors. J Immunol (2014) 0.83
Redundant Roles of Rpn10 and Rpn13 in Recognition of Ubiquitinated Proteins and Cellular Homeostasis. PLoS Genet (2015) 0.82
PAC1 gene knockout reveals an essential role of chaperone-mediated 20S proteasome biogenesis and latent 20S proteasomes in cellular homeostasis. Mol Cell Biol (2010) 0.82
The case for therapeutic proteostasis modulators. Expert Opin Ther Targets (2011) 0.82
Identification of mammalian protein quality control factors by high-throughput cellular imaging. PLoS One (2012) 0.81
The life cycle of the 26S proteasome: from birth, through regulation and function, and onto its death. Cell Res (2016) 0.80
The 26S proteasome and initiation of gene transcription. Biomolecules (2014) 0.79
Genomic evolution of the proteasome system among hemiascomycetous yeasts. J Mol Evol (2007) 0.79
MURF2B, a novel LC3-binding protein, participates with MURF2A in the switch between autophagy and ubiquitin proteasome system during differentiation of C2C12 muscle cells. PLoS One (2013) 0.79
Regulation of PSMB5 protein and β subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3): potential role in bortezomib-mediated anticancer therapy. J Biol Chem (2014) 0.79
Mouse zygote-specific proteasome assembly chaperone important for maternal-to-zygotic transition. Biol Open (2012) 0.79
The Proteasome Stress Regulon Is Controlled by a Pair of NAC Transcription Factors in Arabidopsis. Plant Cell (2016) 0.78
Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma. Leuk Lymphoma (2015) 0.78
PaCS is a novel cytoplasmic structure containing functional proteasome and inducible by cytokines/trophic factors. PLoS One (2013) 0.78
Oxadiazole-isopropylamides as potent and noncovalent proteasome inhibitors. J Med Chem (2013) 0.77
Proteasome activity or expression is not altered by activation of the heat shock transcription factor Hsf1 in cultured fibroblasts or myoblasts. Cell Stress Chaperones (2005) 0.77
Analysis of changes in the proteome of HL-60 promyeloid leukemia cells induced by the proteasome inhibitor PSI. Biochem Pharmacol (2008) 0.77
Biodistribution and Efficacy Studies of the Proteasome Inhibitor BSc2118 in a Mouse Melanoma Model. Transl Oncol (2014) 0.76
siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis. PLoS One (2012) 0.76
Endocellular regulation by free radicals and hydrogen peroxide: key determinants of the inflammatory response. Inflammopharmacology (2014) 0.76
Regulation of Proteome Maintenance Gene Expression by Activators of Peroxisome Proliferator-Activated Receptor α. PPAR Res (2011) 0.76
Role of thioredoxin reductase 1 in dysplastic transformation of human breast epithelial cells triggered by chronic oxidative stress. Sci Rep (2016) 0.75
Determination of differentially regulated proteins upon proteasome inhibition in AML cell lines by the combination of large-scale and targeted quantitative proteomics. Proteomics (2016) 0.75
Reversion of the Arabidopsis rpn12a-1 exon-trap mutation by an intragenic suppressor that weakens the chimeric 5' splice site. F1000Res (2013) 0.75
Inhibition of Proteasome Activity Induces Formation of Alternative Proteasome Complexes. J Biol Chem (2016) 0.75
Immunoproteasomes preserve protein homeostasis upon interferon-induced oxidative stress. Cell (2010) 4.45
HnRNP L stimulates splicing of the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol (2003) 3.22
Impact of remote telemedical management on mortality and hospitalizations in ambulatory patients with chronic heart failure: the telemedical interventional monitoring in heart failure study. Circulation (2011) 2.87
Addition of milk prevents vascular protective effects of tea. Eur Heart J (2007) 2.80
An essential role for tripeptidyl peptidase in the generation of an MHC class I epitope. Nat Immunol (2003) 2.38
Percutaneous transfemoral management of severe secondary tricuspid regurgitation with Edwards Sapien XT bioprosthesis: first-in-man experience. J Am Coll Cardiol (2013) 2.02
Proteasomal degradation is transcriptionally controlled by TCF11 via an ERAD-dependent feedback loop. Mol Cell (2010) 2.01
Molecular targets of tea polyphenols in the cardiovascular system. Cardiovasc Res (2006) 1.92
Circulating proteasomes are markers of cell damage and immunologic activity in autoimmune diseases. J Rheumatol (2002) 1.80
Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation (2002) 1.75
Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J (2005) 1.71
Interferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing. Immunol Rev (2005) 1.71
IFN-gamma-induced immune adaptation of the proteasome system is an accelerated and transient response. Proc Natl Acad Sci U S A (2005) 1.70
Computed tomography angiography and myocardial computed tomography perfusion in patients with coronary stents: prospective intraindividual comparison with conventional coronary angiography. J Am Coll Cardiol (2013) 1.67
Virus-induced type I IFN stimulates generation of immunoproteasomes at the site of infection. J Clin Invest (2006) 1.66
Hepatitis C virus mutation affects proteasomal epitope processing. J Clin Invest (2004) 1.58
Functional significance of a hereditary adenine insertion variant in the 5'-UTR of the endothelin-1 gene. Pharmacogenetics (2003) 1.51
Potent anti-inflammatory effects of low-dose proteasome inhibition in the vascular system. J Mol Med (Berl) (2009) 1.49
Humoral anti-proteasomal autoimmunity in dilated cardiomyopathy. Basic Res Cardiol (2010) 1.47
Emerging roles of immunoproteasomes beyond MHC class I antigen processing. Cell Mol Life Sci (2012) 1.42
Influence of sex on outcome following transcatheter aortic valve implantation (TAVI): systematic review and meta-analysis. J Interv Cardiol (2014) 1.42
Renal sympathetic denervation: early impact on ambulatory resistant hypertension. J Clin Hypertens (Greenwich) (2014) 1.40
MAPPP: MHC class I antigenic peptide processing prediction. Appl Bioinformatics (2003) 1.31
Intravenous recombinant human relaxin in compensated heart failure: a safety, tolerability, and pharmacodynamic trial. J Card Fail (2009) 1.26
Nrf2-dependent upregulation of antioxidative enzymes: a novel pathway for proteasome inhibitor-mediated cardioprotection. Cardiovasc Res (2009) 1.26
Suppression of cardiomyocyte hypertrophy by inhibition of the ubiquitin-proteasome system. Hypertension (2007) 1.26
Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma. Blood (2006) 1.22
The role of tea and tea flavonoids in cardiovascular health. Mol Nutr Food Res (2006) 1.22
Immunoproteasomes at the interface of innate and adaptive immune responses: two faces of one enzyme. Curr Opin Immunol (2012) 1.19
The proteasome maturation protein POMP facilitates major steps of 20S proteasome formation at the endoplasmic reticulum. EMBO Rep (2007) 1.18
Contrast-enhanced MR imaging of atherosclerosis using citrate-coated superparamagnetic iron oxide nanoparticles: calcifying microvesicles as imaging target for plaque characterization. Int J Nanomedicine (2013) 1.17
Proteasome inhibitors: poisons and remedies. Med Res Rev (2008) 1.16
Human immunodeficiency virus-1 Tat protein interacts with distinct proteasomal alpha and beta subunits. FEBS Lett (2003) 1.12
Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB J (2004) 1.11
Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med (2006) 1.10
Differential expression regulation of the alpha and beta subunits of the PA28 proteasome activator in mature dendritic cells. J Immunol (2005) 1.09
The tea flavonoid epigallocatechin-3-gallate reduces cytokine-induced VCAM-1 expression and monocyte adhesion to endothelial cells. Biochem Biophys Res Commun (2004) 1.08
Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension (2004) 1.08
Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res (2009) 1.07
Telemedical Interventional Monitoring in Heart Failure (TIM-HF), a randomized, controlled intervention trial investigating the impact of telemedicine on mortality in ambulatory patients with heart failure: study design. Eur J Heart Fail (2010) 1.07
Expression of the proteasome activator PA28 rescues the presentation of a cytotoxic T lymphocyte epitope on melanoma cells. Cancer Res (2002) 1.06
Maturation of human dendritic cells is accompanied by functional remodelling of the ubiquitin-proteasome system. Int J Biochem Cell Biol (2008) 1.04
The role of the proteasome activator PA28 in MHC class I antigen processing. Mol Immunol (2002) 1.03
Relaxin-a pleiotropic hormone and its emerging role for experimental and clinical therapeutics. Pharmacol Ther (2006) 1.02
Link between organ-specific antigen processing by 20S proteasomes and CD8(+) T cell-mediated autoimmunity. J Exp Med (2002) 1.00
Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol (2002) 0.99
PI31 is a modulator of proteasome formation and antigen processing. Proc Natl Acad Sci U S A (2002) 0.98
Green and black tea are equally potent stimuli of NO production and vasodilation: new insights into tea ingredients involved. Basic Res Cardiol (2008) 0.98
Protection of vascular cells from oxidative stress by proteasome inhibition depends on Nrf2. Cardiovasc Res (2009) 0.96
Current diagnostic concepts to detect coronary artery disease in women. Eur Heart J (2008) 0.95
The flavonoid phloretin suppresses stimulated expression of endothelial adhesion molecules and reduces activation of human platelets. J Nutr (2005) 0.95
Maternal heart disease and pregnancy outcome: a single-centre experience. Eur J Heart Fail (2008) 0.94
Telemedicine in heart failure: pre-specified and exploratory subgroup analyses from the TIM-HF trial. Int J Cardiol (2011) 0.94
Relaxin improves TNF-α-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc Res (2012) 0.93
Redox control of the ubiquitin-proteasome system: from molecular mechanisms to functional significance. Antioxid Redox Signal (2011) 0.93
Impairment of immunoproteasome function by β5i/LMP7 subunit deficiency results in severe enterovirus myocarditis. PLoS Pathog (2011) 0.92
Negative inotropic mediators released from the heart after myocardial ischaemia-reperfusion. Cardiovasc Res (2002) 0.91
Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. J Clin Invest (2015) 0.90
Identification of the pregnancy hormone relaxin as glucocorticoid receptor agonist. FASEB J (2004) 0.90
Comprehensive proteomic and transcriptomic analysis reveals early induction of a protective anti-oxidative stress response by low-dose proteasome inhibition. Proteomics (2009) 0.89
The efficacy of black tea in ameliorating endothelial function is equivalent to that of green tea. Br J Nutr (2007) 0.89
Ongoing coxsackievirus myocarditis is associated with increased formation and activity of myocardial immunoproteasomes. Am J Pathol (2006) 0.88
Alternative splicing in intron 13 of the human eNOS gene: a potential mechanism for regulating eNOS activity. FASEB J (2007) 0.88
Smoking decreases the level of circulating CD34+ progenitor cells in young healthy women--a pilot study. BMC Womens Health (2010) 0.88
Relaxin is a candidate drug for lung preservation: relaxin-induced protection of rat lungs from ischemia-reperfusion injury. J Heart Lung Transplant (2009) 0.87
Immunoproteasomes are important for proteostasis in immune responses. Cell (2013) 0.87
Relaxin inhibits early steps in vascular inflammation. Regul Pept (2010) 0.87
Generation of in silico predicted coxsackievirus B3-derived MHC class I epitopes by proteasomes. Amino Acids (2009) 0.87
Rapid binding of electrostatically stabilized iron oxide nanoparticles to THP-1 monocytic cells via interaction with glycosaminoglycans. Basic Res Cardiol (2013) 0.86
Acute regional improvement of myocardial function after interventional transfemoral aortic valve replacement in aortic stenosis: a speckle tracking echocardiography study. Cardiovasc Ultrasound (2012) 0.86
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol (2003) 0.86
Proteasome activator and antigen-processing aminopeptidases are regulated by virus-induced type I interferon in the hepatitis C virus-infected liver. J Interferon Cytokine Res (2007) 0.85
Epigenetic regulation of cell adhesion and communication by enhancer of zeste homolog 2 in human endothelial cells. Hypertension (2012) 0.85
Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition. Arterioscler Thromb Vasc Biol (2012) 0.85
Effect of statins on the proteasomal activity in mammalian endothelial and vascular smooth muscle cells. Biochem Pharmacol (2005) 0.85
The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure. Eur J Heart Fail (2004) 0.84
Dysfunction in protein clearance by the proteasome: impact on autoinflammatory diseases. Semin Immunopathol (2015) 0.84
Proteasome inhibition prevents experimentally-induced endothelial dysfunction. Life Sci (2009) 0.84
Tumor cell lines expressing the proteasome subunit isoform LMP7E1 exhibit immunoproteasome deficiency. Cancer Res (2006) 0.84
Combined effect of proteasome and calpain inhibition on cisplatin-resistant human melanoma cells. Cancer Res (2006) 0.84
Long-term Doppler hemodynamics and effective orifice areas of Edwards SAPIEN and medtronic CoreValve prostheses after TAVI. Echocardiography (2013) 0.84